scholarly journals Anxiety in gynecology: three clinical cases

2019 ◽  
pp. 172-177
Author(s):  
D. I. Burchakov ◽  
R. A. Chilova
Keyword(s):  
Hormonal Therapy ◽  
Typical Case ◽  
Efficacy And Safety ◽  
Anxiolytic Drug ◽  
Somatic Condition ◽  
Case Vignettes ◽  
Clinical Cases

Tofisopam is an anxiolytic drug, available for prescription by gynecologist. This paper discusses three typical case vignettes, where woman’s anxiety interfered with her somatic condition and responded on tofisopam. There is also a discussion of combination of tofisopam with hormonal therapy and it’s efficacy and safety.

scholarly journals Erythema Dyschromicum Perstans: Identical to Ashy Dermatosis or Not

2015 ◽  
Vol 7 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Takafumi Numata ◽  
Kazutoshi Harada ◽  
Ryoji Tsuboi ◽  
Yoshihiko Mitsuhashi
Keyword(s):  
African American ◽  
Recent Literature ◽  
Clinical Course ◽  
Skin Lesions ◽  
Clinical Findings ◽  
Typical Case ◽  
Unknown Etiology ◽  
Clinical Classification ◽  
Pigmentary Disorders ◽  
Clinical Cases

Erythema dyschromicum perstans (EDP) and ashy dermatosis (AD) are pigmentary disorders of unknown etiology. EDP is usually considered to be identical to AD; however, a new clinical classification for EDP was proposed in the recent literature. Herein, we report a typical case of EDP observed in an African-American man. Interestingly, the late skin lesions in this case fit the criteria of AD as well. While there appear to be a few clinical cases that can be diagnosed as both EDP and AD based on the clinical course, the preponderance of the evidence in the published reports of EDP and AD and the clinical findings reported here strongly suggest that they are two distinct entities in terms of the extent of the inflammation, albeit on the same spectrum of pigment disorders.

scholarly journals Advantages of the Ultralow-dose Hormonal Menopausal Therapy: An Ample Opportunity with Minimal Risks

Doctor Ru ◽  
2021 ◽  
Vol 20 (8) ◽  
pp. 41-47
Author(s):  
S.S. Apetov ◽  
◽  
V.V. Apetova ◽  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Hormone Therapy ◽  
Hormonal Therapy ◽  
Elderly Women ◽  
Sex Hormone ◽  
Efficacy And Safety ◽  
Ultralow Dose ◽  
Post Menopause

Objective of the Review: To analyse the efficacy and safety of the ultralow-dose menopausal hormonal therapy (MHT). Key Points. In developed countries, the life expectancy is growing and the issue of improved quality of life of elderly women is becoming quite acute. On the average, a third (or a half for early menopause) of a modern woman’s life falls on the post-menopause period. Termination of oestrogen synthesis in ovaries during menopause is associated with marked reduction in the quality of life, development of vasomotor symptoms, sleep disturbances, accelerated skin ageing, an increased risk of cardiovascular pathologies and a number of somatic disorders, urinogenital atrophy, osteoporosis, and cognitive disorders. MHT is a proven and efficient means of quality of life improvement; however, the safety of sex hormone therapy in elderly women is still a topical issue. In this article, we are discussing the efficacy and safety of oral MHT drug containing 0.5 mg of 17β-estradiol and 2.5 mg of didrogesteron. Conclusion. The advent of ultralow-dose MHT drugs allowed significantly reducing the number of side effects from sex hormone therapy during post-menopause vs. side effects from higher doses of estradiol with comparable clinical effects. Keywords: menopausal hormonal therapy, ultralow-dose drugs, estradiol, didrogesteron.

Possibility of combined therapy with an oral phosphodiesterase-4 inhibitor (apremilast) and dihydrofolatereductase inhibitor (methotrexate) in patients with psoriatic arthritis plaque psoriasis

2019 ◽  
Vol 74 (5) ◽  
pp. 292-298
Author(s):  
Alexey A. Kubanov ◽  
Olga G. Artamonova ◽  
Arfenya E. Karamova
Keyword(s):  
Psoriatic Arthritis ◽  
Combination Therapy ◽  
Plaque Psoriasis ◽  
Combined Therapy ◽  
Efficacy And Safety ◽  
Severe Plaque Psoriasis ◽  
Phosphodiesterase 4 ◽  
Significant Clinical Improvement ◽  
Phosphodiesterase 4 Inhibitor ◽  
Clinical Cases

Background: Data on the possible combinations of apremilast with other types of psoriasis therapy is limited. Description of clinical cases: We present the data on the efficacy and safety of combination therapy of the selective phosphodiesterase 4 inhibitor and dihydrofolatereductase inhibitor (methotrexate) for the treatment of psoriasis and psoriatic arthritis in patients with moderate-to-severe plaque psoriasis and active psoriatic arthritis with lack of efficacy of methotrexate in the anamnesis. The selective phosphodiesterase 4 inhibitor (apremilast) was administered according to the prescription. The severity psoriatic arthritis of was estimated by PASI. The effectiveness of therapy was evaluated at week 14. Due to the lack of effect, methotrexate was added subcutaneously at week 14. The effectiveness of combination therapy was assessed at week 26. In both cases, the significant clinical improvement was reached (patients reached PASI 75 and PASI 90), a decrease of the psoriatic arthritis activity according to the DAS28 and DAPSA. Conclusion: These clinical cases demonstrate the efficacy and safety of combined therapy with methotrexate and apremilast inpatients with active psoriatic arthritis and moderate to severe plaque psoriasis.

Evaluation of sevoflurane and isoflurane as maintenance agent in buffaloes after glycopyrrolate-xylazine-butorphanol-propofol anaesthesia

2019 ◽  
Author(s):  
R. N. Chaudhary ◽  
Rishi Tayal
Keyword(s):  
Diaphragmatic Hernia ◽  
Biochemical Parameters ◽  
Muscle Relaxation ◽  
Efficacy And Safety ◽  
Blood Biochemical Parameters ◽  
Anaesthetic Agents ◽  
Blood Biochemical ◽  
Partial Rebreathing ◽  
Cardiovascular Depression ◽  
Clinical Cases

The study was aimed to compare the efficacy and safety of isoflurane and sevoflurane as maintenance agent in a balanced anaesthetic combination for buffaloes undergoing diaphragmatic herniorrhaphy. Twelve clinical cases of diaphragmatic hernia in female buffaloes were randomly selected and assigned to two groups (PS and PI) of six animals each. After premedication with glycopyrrolate, xylazine and butorphanol, induction was done with propofol. For maintenance, either sevoflurane (PS) or isoflurane (PI) was used with oxygen through a partial rebreathing system. Clinical, physiological, behavioral, haematological and biochemical parameters were recorded at different intervals. No significant differences were observed in maintenance scores, degree of muscle relaxation as well as haematological and blood biochemical parameters between the groups. The heart and respiratory rates were observed to be less depressed in PS than in PI. The recovery and standing with ataxia in PS was significantly earlier than the PI. Both isoflurane and sevoflurane were found to be safe and effective maintenance anaesthetic agents for buffaloes undergoing diaphragmatic herniorrhaphy; however, the sevoflurane was assessed to be slightly better as maintenance agent because of faster recovery and lesser cardiovascular depression than isoflurane.

scholarly journals TOFISOPAM: PROSPECTS FOR NON-HORMONAL THERAPY OF NEURO-VEGETATIVE AND PSYCHO-EMOTIONAL DISORDERS ASSOCIATED WITH MENOPAUSAL SYNDROME

2017 ◽  
pp. 88-91 ◽  
Author(s):  
Y. E. Dobrokhotova ◽  
L. V. Saprykina
Keyword(s):  
Hormone Therapy ◽  
Emotional Disorders ◽  
Hormonal Therapy ◽  
Hormonal Treatment ◽  
Climacteric Syndrome ◽  
Efficacy And Safety ◽  
Review Of Literature ◽  
Menopausal Syndrome ◽  
Number Of Factors ◽  
Perimenopausal Women

Despite the proven effect of menopausal hormone therapy on menopausal syndrome, a number of factors prevent perimenopausal women from receiving the treatment. The article is a review of literature on the possibility of non-hormonal treatment with tofisopam for neuro-vegetative and psycho-emotional disorders associated with climacteric syndrome. The article tells about the efficacy and safety of the drug taking into account its pharmacodynamic properties.

scholarly journals РОЛЬ МЕСТНОГО ИСПОЛЬЗОВАНИЯ КОНЪЮГИРОВАННОГО ЭСТРОГЕНА В УЛУЧШЕНИИ ИСХОДОВ ОПЕРАТИВНОГО ЛЕЧЕНИЯ ПРОЛАПСА ГЕНИТАЛИЙ

Innova ◽  
2019 ◽  
Vol 15 ◽  
pp. 20-23
Author(s):  
Максумова Н.Б. ◽  
◽  
Ниязметов Р.Э. ◽  
Матякубов Б.Б. ◽  
Усинова З.Б.
Keyword(s):  
Surgical Treatment ◽  
Postoperative Complications ◽  
Hormonal Therapy ◽  
Genital Prolapse ◽  
Efficacy And Safety ◽  
High Efficacy ◽  
Regenerative Processes ◽  
Genitourinary System ◽  
Surgical Methods ◽  
Conjugated Estrogen

The available surgical methods for the treatment of genital prolapse cannot guarantee the absence of complications in the postoperative period and relapse. In this article, we describe the possibilities of preventing postoperative complications and repeated episodes of prolapse of the genital organs of local hormonal therapy with conjugated estrogen (femistrone) preparations, which directly improves the regenerative processes in the tissues of the genitourinary system. Based on our clinical experience, we came to the conclusion about the high efficacy and safety of topical application of conjugated estrogen (femistrone) for 5-7 days in the preparation of the vaginal walls for surgical treatment.

Palbociclib in hormone positive metastatic breast cancer: A real world multicenter Indian experience.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13057-e13057
Author(s):  
Amit Rauthan ◽  
Poonam Patil ◽  
S.P. Somashekhar ◽  
Linu Abraham Jacob ◽  
Lokanatha D ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Hormonal Therapy ◽  
Metastatic Breast ◽  
Standard Of Care ◽  
Second Line ◽  
Efficacy And Safety ◽  
First Line ◽  
Indian Patients ◽  
Visceral Metastases

e13057 Background: Palbociclib, a selective CDK4/6 inhibitor, in combination with hormonal therapy has become the standard of care in the treatment of hormonal positive (HR+) metastatic breast cancer (MBC). There is limited efficacy and safety data in Indian patients. Methods: This is a multicenter retrospective study of real world experience of patients with HR+, Her 2 neu negative MBC who received Palbociclib in 5 centers of south India between Oct 2016 and Aug 2019. Endpoints were overall response rate (ORR), progression free survival (PFS) and toxicity. Results: 133 patients received Palbociclib; 83 (62.4%) in the first line setting (hormone naïve MBC) and 50 (37.6%) in the second line (MBC progressed on at least one line of hormonal therapy). Median age was 56 years (range 48-76). All patients started with 125mg/day. In the 83 first line patients, 46 (55.4%) had denovo MBC, 37 (44.6%) had post-adjuvant relapse. 38 (45.8%) had bone only and 45 (54.2%) had visceral metastases. Letrozole was the companion drug in 76%, Fulvestrant in 18%, Exemestane in 6%. 5 (6%) patients achieved complete response (CR), 54 (65%) partial response (PR), 12 (14.5%) stable disease (SD) and 12 (14.5%) had progressive disease (PD). ORR was 71%. At a median followup of 18 months, the median PFS was not reached (maximum ongoing followup 38 months). The median PFS in the denovo metastatic disease versus relapsed disease was not reached versus 18 months (p = 0.021). The median PFS was significantly better in bone only versus visceral metastases (not reached versus 28 months, p = 0.007). In the 50 second line patients, 15 (30%) had bone only and 35 (70%) had visceral metastases. Companion drug was Fulvestrant in 64%, Letrozole in 20%, Exemestane in 16%. 60% received prior chemotherapy. Best response was CR 3 (6%), PR 23 (46%), SD 4 (8%), PD 17 (34%), not assessed 3 (6%). ORR was 52%. The median PFS was 14 months. PFS in bone only versus visceral disease was 14 months versus 13 months (p = 0.382). Neutropenia was present in 75.2%, thrombocytopenia in 19.5%, anaemia in 18%. Neutropenia was grade 1 in 26%, grade 2 in 51%, grade 3 in 23%; with no febrile neutropenia. 30% had dose delays and 8.2% had dose reduction. Conclusions: Palbociclib has resulted in similar efficacy and safety in Indian patients as the PALOMA trials. Neutropenia was the commonest side effect, which was uncomplicated and easily managed with dose delays. Using CDK4/6 inhibitors with hormonal therapy has become the standard of care in HR+ MBC Indian patients.

Sign in / Sign up

Export Citation Format

Share Document